Novocure Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVCR research report →
Range $20 – $32
Price Chart
About the company
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
- CEO
- Frank Leonard
- IPO
- 2015
- Employees
- 1,605
- HQ
- Baar, CH
Get TickerSpark's AI analysis on NVCR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.25B
- P/E
- -10.12
- Fwd P/E
- 5.64
- PEG
- -0.39
- P/S
- 1.73
- P/B
- 3.57
- EV/EBITDA
- -13.33
- Div Yield
- 0.00%
- Gross Margin
- 77.02%
- Op Margin
- -17.17%
- Net Margin
- -16.78%
- ROE
- -35.81%
- ROIC
- -19.92%
Latest fiscal year · YoY change
- Revenue
- $655.35M+8.3%
- Gross Profit
- $488.47M+4.4%
- Op Income
- $-153,800,000
- Net Income
- $-136,227,000+19.2%
- EPS
- $-1.22+21.8%
- OCF Growth
- -85.9%
- FCF Growth
- -9.3%
- 52W High
- $21.45
- 52W Low
- $9.82
- 50D MA
- $14.40
- 200D MA
- $14.77
- Beta
- 1.08
- RSI (14)
- 28
- Avg Volume
- 1.51M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Novocure delivered record Q3 revenue and improved profitability, led by strong GBM and Japan growth, while Optune Pax faced launch headwinds in the U.S.· October 29, 2026
- Record Q3 net revenue of €193 million, up 16% year over year, with adjusted EBITDA positive at $16 million.
- Active patients rose 19% year over year; GBM patients on therapy reached 4.73 thousand, up 11% year over year and a company record.
- Optune Lua momentum continued in Japan with 255 active patients and $8 million net revenue globally; Japan contributed 110 patients and $4 million.
- Optune Pax was the weak spot: 276 active patients and $3.7 million net revenue, with management citing U.S. practice disruption from diraxonrasib.
- Management raised 2026 guidance for both revenue and adjusted EBITDA and said it remains on track to reach profitability milestones.
Novocure reported Q3 2026 net revenue of €193 million, up 16% year over year. Gross margin was 77% versus 73% in Q3 2025. Net loss was $10 million, versus a $37 million loss a year ago, and loss per share was $0.09. EBITDA loss was $2 million versus a $32 million loss in Q3 2025, while adjusted EBITDA was positive $16 million versus negative $3 million last year. Active patients rose 19% year over year, including 4.73 thousand GBM patients on therapy, up 11% year over year. Optune Pax ended the quarter with 276 active patients and $3.7 million in net revenue. Optune Lua ended with 255 active patients and $8 million in global net revenue, including 110 active patients and $4 million from Japan. For 2026, management raised net revenue guidance to $736 million to $743 million, implying 12% to 13% growth, and said Optune Lua plus Optune Pax should contribute $30 million to $34 million collectively. Full-year adjusted EBITDA guidance was raised to $24 million to $34 million. Cash and investments were $463 million as of September 30. Management said gross margin should remain in the mid- to high-70s in Q4, R&D should be roughly at or below current levels, sales and marketing will mostly leverage the existing force with limited incremental spend for Pax and Maya, and G&A should stay near current levels with minimal inflation-driven increases.
Bill Doyle emphasized that the quarter showed solid execution across the commercial portfolio, with record active patients and record net revenue, plus progress toward profitability. He highlighted continued momentum in Optune Gio and the early success of Optune Lua in Japan, while acknowledging headwinds in the Optune Pax launch. His tone was constructive and confident, saying Novocure is well positioned to carry this momentum into 2027 and that the company is building the infrastructure needed for larger patient populations.
Christoph Brackmann pointed to a strong P&L across the board: €193 million in net revenue, 77% gross margin, a $10 million net loss, and adjusted EBITDA of $16 million. He said the revenue lift came mainly from 19% active-patient growth, plus a $4 million one-time benefit from higher approval rates in the U.S. and Germany, partially offset by a $2 million FX headwind. He also cited $58 million of R&D, $53 million of sales and marketing, $44 million of G&A, and cash and investments of $463 million. He raised 2026 adjusted EBITDA guidance to $24 million to $34 million and said the company expects to keep gross margin in the mid- to high-70s and maintain tight expense discipline.
Analysts focused heavily on the slowdown in Optune Pax, asking whether the sequential decline reflected weaker demand or a broader market issue. Frank Leonard said the main problem was reduced access to practices because diraxonrasib is flooding offices with patients, appeals, and skin-toxicity management, rather than patients abandoning Pax in large numbers. Questions also centered on the path to 2027 growth and profitability; management said it still aspires to double-digit top-line growth and sees Japan and future Pax reimbursement there as important tailwinds. On R&D, management said spending should be flat to slightly declining in 2027 as KEYNOTE-D58 and LUNAR-2 remain significant, then decline further after large phase 3 studies roll off if not replaced by new trials. A final discussion on the Verastem collaboration clarified that PANOVA-5 and PANOVA-6 are intended mainly to establish feasibility, tolerability, and confidence for combining Optune Pax with KRAS inhibitors, not just to measure efficacy.
The core GBM business is growing again, active patients are at record levels, and Japan is emerging as a meaningful growth engine with Optune Lua. Management also raised revenue and adjusted EBITDA guidance, suggesting the company sees sustained commercial momentum and improving operating leverage. The company is still early in new launches, with optionality from Maya and future Pax reimbursement in Japan.
Optune Pax is under pressure in the U.S. because practices are being overwhelmed by diraxonrasib-related volume, appeals, and management issues, limiting Novocure’s access to doctors. Management also acknowledged that Q4 revenue could be below Q3 and that launch timing, reimbursement milestones, and payer adoption remain uncertain. R&D should stay elevated in 2027 because of D58 and LUNAR-2, so the path to higher profitability still depends on continued revenue growth and launch execution.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.3%
- Shares Outstanding
- 116.92M
- Float Shares
- 97.39M
of shares held by institutions
231 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NVCR, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 17.38M | ▲ 2.78K |
| Blackrock, Inc. | 11.86M | ▼ 1.55M |
| Vanguard Group Inc | 10.96M | ▲ 502.37K |
| Soleus Capital Management, L.P. | 9.91M | ▼ 578.99K |
| Vanguard Portfolio Management LLC | 6.49M | ▲ 221.28K |
| Vanguard Capital Management LLC | 4.92M | ▲ 20.35K |
| Morgan Stanley | 4.70M | ▲ 174.73K |
| Quantinno Capital Management LP | 4.22M | ▲ 2.00M |
| State Street Corp | 2.93M | ▲ 60.52K |
| Geode Capital Management, LLC | 2.81M | ▲ 8.91K |
| Wells Fargo & Company/Mn | 2.53M | ▼ 423.14K |
| Renaissance Technologies LLC | 2.12M | ▲ 165.80K |
Held by 384 ETFs
Biggest fund positions in NVCR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | Paravasthu Mukund | sell | 3,079 |
| Nov 9, 26 | Brackmann Christoph | sell | 7,343 |
| Nov 2, 26 | Puri Michal Nath | sell | 660 |
| Jun 30, 26 | Puri Michal Nath | other | 1,905 |
| Jun 30, 26 | Leonard Frank X | other | 1,905 |
| Jun 30, 26 | Ben Arye Barak | other | 1,299 |
| Jun 30, 26 | Danziger Asaf | other | 268 |
| Jun 4, 26 | Leonard Frank X | sell | 34,273 |
| Jun 3, 26 | LEUNG GABRIEL | other | 11,610 |
| Jun 3, 26 | LEUNG GABRIEL | other | 16,999 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NVCR coverage
Recent articles, reports, and earnings notes.
No research on NVCR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NVCR report →Novocure Announces Upcoming Investor Events
businesswire.com · Nov 19
JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer
businesswire.com · Nov 13
FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.
fool.com · Nov 10
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
businesswire.com · Nov 9
Head-To-Head Contrast: Flora Growth (NASDAQ:FLGC) & NovoCure (NASDAQ:NVCR)
defenseworld.net · Nov 6
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
zacks.com · Nov 2
NovoCure: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 1
NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.